The FDA’s New Tzield Approval Fundamentally Alters Stage 3 Pediatric Type 1 Diabetes Management
The FDA’s approval of teplizumab for newly diagnosed pediatric Type 1 diabetes marks a shift from insulin replacement toward preserving remaining beta-cell function through immunotherapy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.